Bacteriology & Clinical Syndromes

Educational study digest pitched at a new ID fellow. Clinical recommendations trace to the cited guidelines and trials; the enrichment box is reviewer synthesis of additional evidence, each claim cited. Not medical advice, and not a substitute for the primary guidelines.

◆Years of migratory seronegative arthritis, then diarrhea and wasting — what unifies it?

A middle-aged man (classic Whipple disease runs roughly three times more often in men) with years of migratory, seronegative large-joint polyarthritis that precedes the gut disease, followed by chronic diarrhea, weight loss, and malabsorption — iron-deficiency anemia and hypoalbuminemia — plus lymphadenopathy and skin hyperpigmentation, has Whipple disease until proven otherwise. The organism is Tropheryma whipplei, a gram-positive actinomycete. Its hallmark is invasion of the small-bowel lamina propria by foamy macrophages that cannot degrade the bacterium and stain strongly PAS-positive; underlying host immunologic defects (macrophage, T-cell, and humoral) permit persistence. Two board-favorite extras: T. whipplei is a recognized cause of culture-negative endocarditis, is found in the stool of children with acute diarrhea, and is resistant to glutaraldehyde.

The detail that changes therapy is CNS involvement: a positive CSF PCR for T. whipplei means the central nervous system is seeded, so treatment must penetrate it. The established approach is an induction phase with a CNS-penetrating agent — ceftriaxone (or penicillin G) for about two weeks — followed by prolonged oral trimethoprim-sulfamethoxazole for roughly a year to clear the intracellular reservoir and prevent neurologic relapse. The discriminator a fellow is tested on: migratory seronegative arthritis for years before any GI symptom, with PAS-positive foamy macrophages on small-bowel biopsy — not a rheumatologic diagnosis.

◆PID with one positive NAAT — which partners get treated, and who gets admitted?

Pelvic inflammatory disease is an ascending infection led by N. gonorrhoeae and C. trachomatis, joined by vaginal flora (Gardnerella vaginalis, Haemophilus influenzae, enteric gram-negative rods, group B streptococcus) and, less often, CMV, Trichomonas vaginalis, Mycoplasma hominis, and Ureaplasma urealyticum. The diagnosis is clinical: a sexually active woman with pelvic or lower-abdominal pain and cervical-motion, uterine, or adnexal tenderness, supported by fever >101°F, mucopurulent cervical discharge or friability, abundant WBCs on saline microscopy, or an elevated ESR/CRP.

The tested point is partner management. Per the CDC 60-day rule, anyone who had sexual contact with the patient in the 60 days before symptom onset should be evaluated, tested, and presumptively treated for both chlamydia and gonorrhea — regardless of which pathogen (if any) the index patient grew. So both of this woman’s partners qualify, and the single positive C. trachomatis NAAT does not narrow partner therapy to chlamydia alone — both organisms are covered empirically. If the last intercourse was >60 days before onset, treat the most recent partner. Admit — rather than treat as an outpatient — when a surgical emergency such as appendicitis cannot be excluded, for a tubo-ovarian abscess, in pregnancy, for severe illness with nausea/vomiting or oral temperature >38.5°C (101°F), when the patient cannot tolerate or follow an oral regimen, or when there is no response to oral therapy.

◆A cruise-ship cluster with diplopia, dysphagia, and descending weakness — what, and what first?

Blurred vision, dysphonia, dysarthria, dysphagia, sluggish dilated pupils, and then symmetric, descending motor weakness — in an afebrile patient with a supple neck, normal mentation, and preserved sensation, and with twenty fellow travelers similarly ill — is botulism. Clostridium botulinum is a gram-positive obligate anaerobe with a subterminal spore; its spores live in soil and marine sediment, and it elaborates a heat-labile neurotoxin that binds the presynaptic neuromuscular junction and blocks acetylcholine release there and at cholinergic autonomic sites (hence the constipation, dry mouth, and dilated pupils). A shared-meal point-source cluster points to the foodborne form. The three forms: foodborne (preformed toxin ingested — heating inactivates the toxin but not the spores, classically in home-preserved foods); wound (embedded spores elaborate toxin in the wound, e.g., in an injection drug user); and intestinal/infant (spore colonization with in-vivo toxin production). It is also a recognized bioterrorism agent by aerosol or food.

Diagnosis rests on clinical suspicion confirmed by toxin detection in serum, stool, vomitus, or food and culture of gastric aspirate/wound/stool — toxin assays are more likely positive early, stool culture more likely positive later. Management is what the vignette rewards: give equine antitoxin as soon as botulism is suspected — do not wait for confirmatory testing, because antitoxin only neutralizes toxin still circulating, and recovery otherwise requires slow regrowth of presynaptic axons and new synapses. Monitor respiratory status closely and intubate early. Do not give antibiotics in foodborne or intestinal botulism — lysing the organisms can release more toxin; wound botulism is the exception, needing extensive debridement alongside antitoxin.

◆Necrotizing infection after an open fracture bathed in warm estuary water — which bug, and how treated?

A patient with poorly controlled diabetes sustains open femoral and tibial fractures with vascular injury, works in warm brackish and coastal estuary/Gulf waters (oyster and fishing work), and over 48 hours develops pain out of proportion and a rapidly advancing soft-tissue infection: think necrotizing infection due to Aeromonas (typically A. hydrophila). Aeromonas is a gram-negative rod of fresh and brackish water and soil, and its signature setup is a traumatic wound contaminated by natural water (the other classic exposure is medicinal leech therapy). It behaves as aggressively as the other water-borne necrotizers such as Vibrio vulnificus.

Treatment has two non-negotiable arms. First, early, aggressive surgical debridement for source control — the operative decision, not the antibiotic, drives survival in necrotizing infection. Second, antimicrobials chosen around the organism’s resistance: Aeromonas carries inducible β-lactamases (including AmpC and metallo-β-lactamase/carbapenemase activity), so it is intrinsically resistant to penicillins and unreliable against many β-lactams. Cover it with a fluoroquinolone (e.g., ciprofloxacin) or a third- or fourth-generation cephalosporin, commonly combined with doxycycline — a regimen that parallels the doxycycline-plus-cephalosporin approach used for Vibrio. The discriminator: a water-contaminated traumatic wound turning necrotic points to Aeromonas, and empiric therapy must not lean on a plain penicillin.

◆A college student with fever, purpura, and lethargy — what does the roommate need?

Fever with rapidly spreading purpura and lethargy in a young adult is invasive meningococcal disease, and the question tests the contact, not the patient. Close contacts receive antimicrobial chemoprophylaxis regardless of vaccination status — vaccination does not cover every serogroup and does not eliminate nasopharyngeal carriage, so “she was vaccinated” never removes the indication. Close contacts are defined as household members (the roommate qualifies), childcare-center contacts, and anyone directly exposed to the patient’s oral/respiratory secretions — kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal-tube management — in the 7 days before symptom onset. Health-care personnel need prophylaxis only if they managed the airway or were exposed to respiratory secretions; routine bedside care does not qualify. Acceptable regimens include rifampin 600 mg twice daily for 2 days, ceftriaxone 250 mg IM once, or ciprofloxacin 500 mg orally once, given as promptly as possible. So the roommate’s correct next step is chemoprophylaxis — not “no prophylaxis needed.”

◆RUQ pain in a young woman with PID and “violin-string” adhesions — what is it?

Right-upper-quadrant pain and hepatic tenderness in a young woman with PID, and laparoscopy or imaging showing “violin-string” adhesions between the liver capsule and the parietal peritoneum, is Fitz-Hugh–Curtis syndrome — perihepatitis. It arises by direct extension of N. gonorrhoeae or C. trachomatis from the fallopian tube to the liver capsule and overlying peritoneum (occasional lymphatic or hematogenous spread explains the rare male case). Clinically there is abdominal pain, hepatic tenderness, and RUQ peritoneal inflammatory signs, with or without overt PID — many women lack pelvic symptoms, which is exactly why it gets missed. The syndrome is commonly mistaken for acute cholecystitis or viral hepatitis, so it belongs in the differential of RUQ pain in any young, sexually active woman; biliary imaging and transaminases are typically unremarkable, and the treatment is that of the underlying STI/PID. The discriminator is the violin-string adhesions with an STI etiology, not gallbladder or hepatocellular disease.

◆Why give an aminoglycoside once daily instead of in divided doses?

Aminoglycosides bind irreversibly to the bacterial 30S ribosomal subunit, causing misreading and arrest of protein synthesis. That mechanism produces two pharmacodynamic features: concentration-dependent killing (a higher peak relative to the MIC kills faster and more completely) and a long post-antibiotic effect — suppression persists after serum levels fall below the MIC because the ribosomal damage lingers. Extended-interval (once-daily) dosing exploits both: it delivers a high peak to maximize peak/MIC killing, then allows a low trough so that cochlear and renal-cortical drug can wash out. Because proximal-tubular uptake of aminoglycoside is saturable, fewer high exposures per day mean less cumulative tubular accumulation. Hence the primary rationale on the exam is reduced nephrotoxicity — not that monitoring becomes unnecessary, that the course is shortened, that audiometry is eliminated, or that cure rates always rise.

It is worth holding the whole pharmacodynamic map in one place, because “how you dose it” follows directly from “what drives the kill”:

◆Meningitis three days after starting ibuprofen in a lupus patient — what nails it?

A woman with SLE develops headache, fever, neck stiffness, and photophobia days after starting ibuprofen for a flare. Her CSF shows 850 WBC/µL with 85% neutrophils, protein 120 mg/dL, and glucose 55 mg/dL against a serum glucose of 100 (a normal ratio), with a negative Gram stain and cultures pending. This is drug-induced (NSAID) aseptic meningitis. The trap is that a neutrophil-predominant CSF looks bacterial — but drug-induced aseptic meningitis is one of the few “aseptic” meningitides that is neutrophilic rather than lymphocytic, and it does so with a sterile Gram stain and preserved glucose. Among the offered CSF findings, the feature that most strongly supports the diagnosis is the neutrophilic pleocytosis with a negative Gram stain: elevated protein and the presence of fever/nuchal rigidity are nonspecific and shared with bacterial meningitis, and the glucose here is normal rather than low. Classic culprits are NSAIDs (ibuprofen especially, and notably in lupus/connective-tissue disease), TMP-SMX, and IVIG. The course is benign: symptoms resolve within days of stopping the drug, and they recur on rechallenge — which both confirms the diagnosis and warns against re-exposure.

◆A postoperative wound growing carbapenem-resistant K. pneumoniae with a metallo-β-lactamase — which regimen?

Fifteen days after intramedullary nailing of a tibial fracture, a patient has purulent discharge from the surgical site and fever spikes >38°C, with WBC 15.6K and CRP 13 mg/dL; blood and wound cultures grow Klebsiella pneumoniae, and a point-of-care test identifies a metallo-β-lactamase (MBL). The preferred regimen is ceftazidime-avibactam plus aztreonam. The logic is mechanistic. MBLs hydrolyze all β-lactams including carbapenems and are not inhibited by avibactam, vaborbactam, or relebactam — so meropenem-vaborbactam and imipenem-cilastatin-relebactam, whose inhibitors only add coverage for serine carbapenemases such as KPC, fail against an MBL. Aztreonam, a monobactam, is intrinsically stable to MBL hydrolysis; but MBL producers almost always co-produce serine β-lactamases (ESBL, AmpC, KPC, OXA) that would destroy aztreonam — so avibactam, supplied by ceftazidime-avibactam, is added to shield the aztreonam. Doxycycline and polymyxin-B are not preferred for this deep, bacteremic bone infection, and tigecycline/eravacycline should not be used for bacteremia or UTI at all.

The same framework governs the neighboring board bug, difficult-to-treat (DTR) Pseudomonas aeruginosa — resistant to piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem-cilastatin, ciprofloxacin, and levofloxacin — where ceftolozane-tazobactam is a lead agent (though rising resistance is a concern). And for CRE confined to the urinary tract, older agents may suffice when susceptible: fluoroquinolones, TMP-SMX, nitrofurantoin, fosfomycin, pivmecillinam, aminoglycosides (tobramycin/amikacin), and colistin. The discriminator to carry: only the aztreonam-containing regimen covers a metallo-β-lactamase; the newer β-lactam/β-lactamase-inhibitor combinations cover serine carbapenemases only.

◆Isolated severe thrombocytopenia ten days into TMP-SMX — what is the mechanism?

A woman started on trimethoprim-sulfamethoxazole for a UTI presents about ten days later with petechiae and oral hemorrhagic bullae, a platelet count of 3 × 10³/mm³, but a normal hemoglobin and white-cell count, no schistocytes, and normal coagulation studies. The mechanism is immune-mediated platelet destruction by drug-dependent antibodies — drug-induced immune thrombocytopenia (DITP) — not marrow suppression and not a consumptive process. The timing is the tell: in a first-time user, DITP follows drug exposure of at least 5–7 days and typically presents about 7–10 days after the drug is started, with severe thrombocytopenia often <10 × 10³/mm³. The isolated thrombocytopenia with normal red and white cells, the absence of schistocytes, and normal coagulation exclude TTP and DIC. Management is straightforward and decisive: stop the offending drug immediately, after which platelet counts usually recover within 1–4 days. Any acute thrombocytopenia <20,000/mm³ of unclear cause with a recently started drug should raise strong suspicion for DITP.

Sources: Whipple disease review (Boumaza et al, Lancet Infect Dis 2022;22(10):e280–e291); CDC Sexually Transmitted Infections Treatment Guidelines, 2021 (PID 60-day partner rule; perihepatitis); CDC guidance on meningococcal disease chemoprophylaxis for close contacts; IDSA 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (Clin Infect Dis 2024; doi:10.1093/cid/ciae403; PMID 39108079); Eur J Clin Microbiol Infect Dis 2025 (doi:10.1007/s10096-025-05080-1); meropenem-vaborbactam vs ceftazidime-avibactam for KPC (Antimicrob Agents Chemother 2020;64(5):e02313-19; doi:10.1128/AAC.02313-19); drug-induced immune thrombocytopenia review (PMID 29492352).